Patents by Inventor Ayaka AKIBA

Ayaka AKIBA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NY-ESO-1-CONTAINING ARTIFICIAL ADJUVANT VECTOR CELL FOR USE IN TREATMENT OF CANCER
    Publication number: 20230330200
    Abstract: An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.
    Type: Application
    Filed: May 15, 2023
    Publication date: October 19, 2023
    Applicants: ASTELLAS PHARMA INC., RIKEN
    Inventors: Ayaka AKIBA, Tatsuya OKUDAIRA, Yasuhide MASUHARA, Keisuke OHSUMI, Shinichiro FUJII
  • NY-ESO-1-containing artificial adjuvant vector cell for use in treatment of cancer
    Patent number: 11672851
    Abstract: An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: June 13, 2023
    Assignees: RIKEN, ASTELLAS PHARMA INC.
    Inventors: Ayaka Akiba, Tatsuya Okudaira, Yasuhide Masuhara, Keisuke Ohsumi, Shinichiro Fujii
  • NY-ESO-1-CONTAINING ARTIFICIAL ADJUVANT VECTOR CELL FOR USE IN TREATMENT OF CANCER
    Publication number: 20230000965
    Abstract: An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.
    Type: Application
    Filed: December 1, 2020
    Publication date: January 5, 2023
    Applicants: ASTELLAS PHARMA INC., RIKEN
    Inventors: Ayaka AKIBA, Tatsuya OKUDAIRA, Yasuhide MASUHARA, Keisuke OHSUMI, Shinichiro FUJII